About the Company
MiMedx Group is a biomedical company based in Marietta, Georgia, founded in 2008. It is traded on the NASDAQ as MDXG. The CEO is Tim Wright. Using tissues from birth such as the placenta, amniotic sac, and umbilical cord, MiMedx creates skin for skin grafts. With the arrival of Wright in May 2019, the company accelerated the process of working with auditors and regulators to resolve legal and financial issues created by the previous management (see ‘History’). Wright also began a cultural and financial turnaround, assembling a new senior management team by August 2019 to instill “transparency, truthfulness, and timeliness” in communications and business dealings. As of December 2020, the company had approximately 735 employees.By August 2020, MiMedx had raised $150 million in concurrent private equity and debt financings; completed a required financial restatement; and filed its 2019 annual report and 2020 first-quarter report.MiMedx's application to relist its common stock on the NASDAQ was approved on October 30, 2020. The company had been delisted from the NASDAQ in November 2018 and had traded on OTC Pink until relisting. As of November 2020, MiMedx had supplied more than two million allografts for skin grafts to address persistent wounds such as diabetic foot ulcers that often result in amputation, burns, and other urgent health issues.
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
863
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MDXG News
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will ...
MiMedx Group (NASDAQ: MDXG)
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn ...
MDXG: Legal Avenues
MDXG READ THE FULL MDXG RESEARCH REPORT Since the report of 2023 full year results on February 28th, MiMedx Group, Inc.
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
MARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into an agreement with TELA Bio ...
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
March 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a ...
TELA Bio Sells NIVIS Distribution Rights to MiMedx in Multi-Million Dollar Deal
Inc. (NASDAQ: TELA), a key player in the development of innovative medical devices, has announced the sale of its ...
MiMedx Group Inc MDXG
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
MiMedx Group Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Mimedx Group Inc
Analysts say these cheap stocks have plenty of upside.
Loading the latest forecasts...